Literature DB >> 25734547

Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects.

Shiroh Tanoue1, Li-Yuan Chang1, Yonghai Li1, David E Kaplan2.   

Abstract

UNLABELLED: Few studies have investigated the impact of liver cirrhosis on dendritic cell function. The purpose of this study was to compare the activation and antigen-presentation capacity of monocyte-derived dendritic cells (MoDC) from cirrhotic patients (CIR) relative to healthy donors (HD). MoDC from CIR and HD were matured, phenotyped, irradiated and pulsed with 15mer peptides for two hepatocellular carcinoma-related antigens, alphafetoprotein and glypican-3, then co-cultured with autologous T-cells. Expanded T-cells were evaluated by interferon-gamma ELISPOT and intracellular staining. 15 CIR and 7 HD were studied. While CD14+ monocytes from CIR displayed enhanced M2 polarization, under MoDC-polarizing conditions, we identified no significant difference between HD and CIR in maturation-induced upregulation of co-stimulation markers. Furthermore, no significant differences were observed between CIR and HD in subsequent expansion of tumor antigen-specific IFNγ+ T-cells.
CONCLUSION: MoDCs isolated from cirrhotic individuals retain similar capacity for in vitro activation, maturation and antigen-presentation as those from healthy donors. Published by Elsevier Inc.

Entities:  

Keywords:  Cirrhosis; Dendritic cell; Glypican-3; Hepatitis C; Human; M1 macrophage; M2 macrophage; Monocyte

Mesh:

Substances:

Year:  2015        PMID: 25734547      PMCID: PMC4405471          DOI: 10.1016/j.cellimm.2015.02.008

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  52 in total

1.  Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors.

Authors:  Marc Dauer; Bianca Obermaier; Jan Herten; Carola Haerle; Katrin Pohl; Simon Rothenfusser; Max Schnurr; Stefan Endres; Andreas Eigler
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

2.  Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection.

Authors:  C Bain; A Fatmi; F Zoulim; J P Zarski; C Trépo; G Inchauspé
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

Review 3.  Global cancer statistics in the year 2000.

Authors:  D M Parkin
Journal:  Lancet Oncol       Date:  2001-09       Impact factor: 41.316

4.  Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice.

Authors:  Hiroto Kayashima; Takeo Toshima; Shinji Okano; Akinobu Taketomi; Noboru Harada; Yo-Ichi Yamashita; Yukihiro Tomita; Ken Shirabe; Yoshihiko Maehara
Journal:  J Immunol       Date:  2010-05-24       Impact factor: 5.422

5.  A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer.

Authors:  Yukio Iwashita; Kouichirou Tahara; Shigeru Goto; Atsushi Sasaki; Seiichiro Kai; Masataka Seike; Chao-Long Chen; Katsunori Kawano; Seigo Kitano
Journal:  Cancer Immunol Immunother       Date:  2003-02-06       Impact factor: 6.968

6.  Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses.

Authors:  Pablo Sarobe; Juan José Lasarte; Aintzane Zabaleta; Laura Arribillaga; Ainhoa Arina; Ignacio Melero; Francisco Borrás-Cuesta; Jesús Prieto
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 7.  The critical role of type-1 innate and acquired immunity in tumor immunotherapy.

Authors:  Hiroaki Ikeda; Kenji Chamoto; Takemasa Tsuji; Yoshinori Suzuki; Daiko Wakita; Tsuguhide Takeshima; Takashi Nishimura
Journal:  Cancer Sci       Date:  2004-09       Impact factor: 6.716

8.  Additive inhibition of dendritic cell allostimulatory capacity by alcohol and hepatitis C is not restored by DC maturation and involves abnormal IL-10 and IL-2 induction.

Authors:  Angela Dolganiuc; Karen Kodys; Andrea Kopasz; Christopher Marshall; Pranoti Mandrekar; Gyongyi Szabo
Journal:  Alcohol Clin Exp Res       Date:  2003-06       Impact factor: 3.455

9.  Presence of functional dendritic cells in patients chronically infected with hepatitis C virus.

Authors:  Randy S Longman; Andrew H Talal; Ira M Jacobson; Matthew L Albert; Charles M Rice
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

10.  Acute alcohol consumption inhibits accessory cell function of monocytes and dendritic cells.

Authors:  Gyongyi Szabo; Donna Catalano; Bernadette White; Pranoti Mandrekar
Journal:  Alcohol Clin Exp Res       Date:  2004-05       Impact factor: 3.455

View more
  2 in total

Review 1.  Cirrhosis-associated immune dysfunction.

Authors:  Agustín Albillos; Rosa Martin-Mateos; Schalk Van der Merwe; Reiner Wiest; Rajiv Jalan; Melchor Álvarez-Mon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-10-26       Impact factor: 46.802

Review 2.  Causes and Consequences of Innate Immune Dysfunction in Cirrhosis.

Authors:  Katharine Margaret Irvine; Isanka Ratnasekera; Elizabeth E Powell; David Arthur Hume
Journal:  Front Immunol       Date:  2019-02-25       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.